KR20160141463A - Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis - Google Patents
Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis Download PDFInfo
- Publication number
- KR20160141463A KR20160141463A KR1020150077153A KR20150077153A KR20160141463A KR 20160141463 A KR20160141463 A KR 20160141463A KR 1020150077153 A KR1020150077153 A KR 1020150077153A KR 20150077153 A KR20150077153 A KR 20150077153A KR 20160141463 A KR20160141463 A KR 20160141463A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- antioxidant
- composition
- present
- inflammatory
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 23
- 241000838298 Aralia continentalis Species 0.000 title abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 25
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 78
- 229930003935 flavonoid Natural products 0.000 claims description 16
- 235000017173 flavonoids Nutrition 0.000 claims description 16
- 150000002215 flavonoids Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 15
- 235000013824 polyphenols Nutrition 0.000 claims description 15
- 230000002292 Radical scavenging effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000000287 crude extract Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 235000006708 antioxidants Nutrition 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241000582770 Salvelinus neiva Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940106579 hops extract Drugs 0.000 description 1
- 239000001906 humulus lupulus l. absolute Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
The present invention relates to an antioxidant and antiinflammatory composition, and more particularly, to an antioxidant and antiinflammatory composition containing a non-toxic extract as a main ingredient.
In vivo, a significant amount of free radicals are produced during the oxidation process for energy production. When large amounts of active oxygen are generated instantaneously or chronic active oxygen is generated, it strongly reacts with the constituents of the cells, damaging the cells and tissues. Continuous damage causes DNA denaturation, lipid oxidation, proteolysis and the like.
In the body, superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT), glutathione reductase, glutathione-S-transferase ), But it has limitations to defend against proteolysis and DNA damages by only the activity of antioxidant enzymes in the human body due to various environmental pollutants, smoking, stress, etc., which are increased along with industrialization have.
Thus, synthetic materials such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) have been developed as antioxidants, but in these cases, ingestion of large quantities may cause many side effects Research is needed to find safe antioxidants derived from natural substances.
On the other hand, inflammation is a defense mechanism to prevent damage to human tissues caused by infection. It involves symptoms such as development, fever and pain, removes pathogenic substances, and regenerates tissues to find normal structures and functions. However, if the antigen is not removed or the internal substance causes the inflammatory reaction to occur excessively or continuously, it promotes mucosal injury and causes various chronic diseases such as neurodegenerative diseases and cancer.
In the human immune response, macrophages are involved in and regulate the production of inflammatory mediators such as nitric oxide (NO), prostaglandin (PG), proinflammatory cytokines, These inflammatory mediators induce inflammatory responses and act as pre-human defense mechanisms, but if the host's immune response does not respond appropriately, it will cause inflammatory diseases and become a problem.
Thus, there is a need for the development of anti-inflammatory agents that safely and effectively inhibit and regulate excessive inflammatory responses.
SUMMARY OF THE INVENTION The present invention has been made in order to solve the problems of the prior art,
It is an object of the present invention to provide an antioxidative and antiinflammatory composition comprising an extract of a natural substance ( Aralia continentalis Kitagawa).
It is another object of the present invention to provide a natural functional food having antioxidant and anti-inflammatory functions which comprises the above composition as an active ingredient.
According to an aspect of the present invention,
An antioxidant or anti-inflammatory composition comprising a fragrance extract as an active ingredient.
In addition,
An antioxidant or antiinflammatory agent containing the composition, and a functional food.
The composition comprising the fragrance extract of the present invention as an active ingredient provides antioxidative and anti-inflammatory effects through excellent radical scavenging ability, inhibition of nitrogen monoxide (NO) formation, and the like.
FIG. 1 is a graph showing the survival rate of BV-2 cells according to the concentration of non-toxic extract using MTT assay.
FIG. 2 is a graph showing the amount of nitrogen monoxide (NO) produced in BV-2 microglial cells according to the concentration of non-toxic extract under conditions of LPS (100 ng / ml).
Aralia continentalis Kitagawa is a perennial herbaceous plant belonging to Araliaceae. It is widely distributed in East Asian countries such as Korea, Japan, and China. It is also known as Aralia continentalis Kitagawa.
The roots mainly used as medicinal parts include 1 to 2% of essential oil, about 0.07% of stearic acid, resin, salicylic acid and diterpenic acid I and II, copper, manganese and nickel as trace elements, It is widely used for treatment of paralysis, paralysis, and the like. The stem and leaves of virulence are used as a fever and cough medicine in the private sector, and are used for the treatment of nervous breakdown, sexual dysfunction, kidney disease, and diabetes. Alcoholic extracts of roasted roots have an exciting effect on the central nervous system and hypotensive effects are known.
The inventors of the present invention have found that the extracts of chewing gum have an activity of significantly lowering the oxidation reaction and the inflammation reaction while studying natural products having safe and adverse effects and having excellent antioxidative and antiinflammatory effects, and completed the present invention.
Hereinafter, the present invention will be described in detail.
The present invention provides an antioxidant or anti-inflammatory composition comprising a fragrance extract as an active ingredient.
The fragrant extract of the present invention extracts leaves, stems and / or roots of the false grains with water, alcohol or a mixed solvent of water and alcohol. It is more preferable that the alcohol is ethanol in view of increasing the extraction yield of the functional ingredient.
As the extraction method, ordinary extraction methods such as cold-pressing, warm-up, heating, and fractionation using the above-mentioned solvent can be used, but the present invention is not limited thereto.
More specifically, the fragrant extract of the present invention is prepared by adding ethanol in an amount of 1 to 10 L, more preferably 5 to 10 L, to 1 g of dried fructose or powder, preferably 20 to 100 ° C, more preferably 20 To 40 < [deg.] ≫ C.
In addition, the fragrant extract of the present invention can be prepared by extracting for preferably 10 to 100 hours, more preferably 40 to 80 hours, further preferably 48 to 72 hours, followed by filtration.
More preferably, the filtrate can be produced by concentrating the filtrate under reduced pressure.
The extraction in the extraction step may be repeated twice or more as necessary, and the extract solution obtained after filtration may be lyophilized or dried under reduced pressure to give a powdery form.
The fragrant extract of the present invention is characterized by containing polyphenol containing flavonoids as a constituent thereof.
Specific examples of the polyphenols include, but are not limited to, protocatechinic acid and catechin in addition to flavonoids.
The content of polyphenols and flavonoids contained in the false lipid extract may vary somewhat depending on the extraction method, raw materials, etc. Generally, the polyphenol and flavonoid are mixed with 12 to 14 g of polyphenol, 3 to 6 μg of flavonoid . ≪ / RTI >
The fragrant extract of the present invention contains a polyphenol component and can have an antioxidative action by activating radical scavenging.
The non-toxic extract of the present invention has a radical scavenging activity at a concentration of preferably 10 to 500 μg / mL, more preferably 10 to 100 μg / mL, more preferably 80 to 100 μg / mL, But is not limited thereto. When the concentration of the fragrant extract is within the above range, the toxicity of the fragrant extract is not observed and the radical scavenging activity is excellent.
In addition, the anti-inflammatory activity of the fragrant extract of the present invention can be judged to be caused by the flavonoid component, and the anti-inflammatory function of the fragrant extract can be confirmed by the action of weakening the production of nitrogen monoxide (NO).
Nitric oxide (NO) mediates important physiological functions such as homeostasis of blood vessels and induction of apoptosis in a normal physiological state, but a large amount of nitrogen monoxide (NO) kills normal cells and induces inflammation, It acts as a cause of disease. Therefore, the action of weakening the production of nitrogen monoxide (NO) can be judged as anti-inflammatory action.
The non-toxic extract of the present invention may contain nitrogen monoxide (NO) at a concentration of preferably 100 to 1000 μg / mL, more preferably 500 to 1000 μg / mL, more preferably 900 to 1000 μg / mL, But the present invention is not limited thereto. When the concentration of the extract obtained from the extract is within the above range, the effect of inhibiting the production of nitrogen monoxide (NO) is remarkable, and it is possible to exhibit excellent anti-inflammatory activity. Exceeding the above range is not preferable because the improvement in the effect on concentration is insignificant and toxicity may appear.
It is also possible that the antioxidant, anti-inflammatory composition comprising the fragile extract of the present invention further comprises components exhibiting the same or similar functions. Examples of the components exhibiting the same or similar functions include, but are not limited to, elm, whitetoptera, and non-hops extract.
The composition of the present invention can be administered parenterally or orally according to a desired method. The dose may vary according to the weight, age, sex, health condition, diet, administration time, administration method, It is possible to appropriately adjust the range thereof, and it is more preferable to administer them once or several times a day.
The composition of the present invention may be added to the medicament for the activity of an antioxidant or anti-inflammatory reaction. That is, antioxidant or anti-inflammatory drugs containing the composition of the present invention are also included in the present invention.
Specific examples of the medicament include, but are not limited to, pills, tablets, and capsules.
The composition of the present invention may be added to a health food for antioxidant or anti-inflammatory activity. That is, the functional food for antioxidant or anti-inflammation including the composition of the present invention is also included in the present invention.
The kind of the food includes a health functional food in a conventional sense, but is not particularly limited, and specific examples thereof include beverage, candy, and homework.
Hereinafter, the present invention will be described in more detail with reference to examples. However, the following examples illustrate the present invention and the present invention is not limited by the following examples, and various modifications and changes may be made. The scope of the present invention will be determined by the technical idea of the following claims.
< Example > Solo Preparation of extract
A. continentalis Kitagawa used in this experiment was cultivated in Jecheon, Chungbuk Province and dried.
Example One.
1 kg of the dried chewing gum was extracted with 10 times (w / v) 70% ethanol (1000 L) at 25 캜 for 72 hours, filtered through a filter paper (Whatman NO.3, England) and transferred to a vacuum evaporator (R- Switerland) and then lyophilized to obtain 122.3 g of a pure ethanol extract. At this time, the extraction yield was 12.23%.
< Experimental Example >
Experimental Example One. Solo Experiments to determine the content of polyphenols and flavonoids in extracts
(1) Measurement of polyphenol content
The content of polyphenols in the extract was determined by Folin-Denis method.
Dissolve 1 mg of the crude extract of Example 1 in 1 mL of distilled water, add 2 mL of a 2-fold diluted Folin reagent (Sigma Aldrich) to 2 mL of
At this time, a standard curve using gallic acid was prepared by measuring the absorbance at 700 nm in the same manner as above so that the final concentration of gallic acid was 0, 5, 25, 50 or 75 μg / mL.
The content of polyphenol present in the simvastatin extract was measured with gallic acid as a reference material. The results of repeated experiments were shown in Table 1 below, and the standard deviation (mean SD) . The total polyphenol content of the extract was 12.88 mg / g.
(2) Measurement of flavonoid content
The content of flavonoids in the extract was determined by the Nieva Moreno method.
10% aluminum nitrate, 0.1 mL of 1 M potassium acetate and 4.3 mL of 80% ethanol were added to 0.5 mL of a mixture of 0.1 mL of the extract of the extract of Example 1 and 0.9 mL of 80% ethanol, and the mixture was allowed to stand at room temperature for 40 minutes. Absorbance was measured at 415 nm.
The total flavonoid content was determined from a standard curve prepared using quercetin. That is, the content of flavonoid was measured with quercetin as a reference material, and the results of repeated experiments were shown in Table 1 below and the standard deviation (mean ± SD) with respect to the average value was described. The flavonoid content of the extract was 4.54 mg / g.
(μg / mg)
(μg / mg)
( Aralia continentalis Kitagawa)
Experimental Example 2. α-α- Diphenyl -β- picrylhydrazyl ( DPPH ) Radical Measurement of scavenging activity
The free radical scavenging activity of the extract was determined by using the reducing power against the stable radical α-α-Diphenyl-β-picrylhydrazyl (DPPH) radical. The antioxidant capacity of DPPH was measured by using DPPH as a relatively stable active radical having a deep purple color and being reduced by an antioxidant, an aromatic amine, or the like to discolor the color.
The fragrant extract of Example 1 was dissolved in 99% methanol and diluted to a concentration of 10, 50, and 100 μg / mL. To 800 μL of each dilution, 200 μL of 0.15 mM DPPH solution dissolved in 99% methanol was added and allowed to stand at room temperature for 30 minutes. Absorbance was measured at 517 nm and the experiment was repeated at least 3 times.
The free radical scavenging activity of each sample was expressed as the RC 50 value, which is the concentration of the sample required to reduce the DPPH radical to 1/2 after 30 minutes of reaction, and is expressed as the standard deviation (mean SD) for the mean value.
In order to compare the free radical scavenging activity of the extract, the scavenging activity of the DPPH radical was measured using L-ascorbic acid, which is a natural antioxidant, and is shown in Table 2 below.
As a result, DPPH radical scavenging activity was 3.16, 20.53 and 63.16% at the concentration of 10, 50 or 100 μg / mL, respectively, and the RC 50 value was about 83.96 μg / mL, indicating excellent DPPH radical scavenging ability.
The ascorbic acid used as a positive control showed DPPH radical scavenging activity at about 0.5 or 1 μg / mL at about 16.84 and 57.89%, respectively, and RC 50 The value was measured to be 0.90 μg / mL.
(μg / mL)
(Scavenging effect)
(μg / mL)
( Aralia continentalis Kitagawa)
(L-ascorbic acid)
Experimental Example 3. Solo Cytotoxicity and nitric oxide (NO) production inhibitory effect of extract
The microglia cell line BV-2 cells used in this experiment were purchased from Harvard University. BV-2 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS; Gibco, BRL, USA), 100 μg / mL penicillin (Gibco, BRL, USA) and 100 μg / mL streptomycin 1640 medium (Gibco, BRL, USA) at 37 ° C in the presence of 5% CO 2 for 2 to 3 days.
(1) Cytotoxicity measurement
In order to determine if the extract was toxic to cells, experiments were carried out using the cell viability assay (MTT assay) according to the method of Carmichael.
BV-2 cells were seeded at a concentration of 1 × 10 5 cells / well in a 96-well plate. After 24 hours of culture, the medium was removed, and the crude extract isolated from 200 μL of RPMI-1640 medium supplemented with LPS (100 ng / Samples (100, 250, 500, 1000 μg / mL) were added to each well and incubated for 24 hours at 37 ° C in the presence of 5% CO 2 .
To this, 20 μL of MTT solution prepared at a concentration of 5 mg / mL in phosphate buffer saline (PBS, pH 7.4) was added and cultured for 4 hours in the same culture condition. The supernatant was removed and 100 μL of DMSO was added to each well. After stirring for 10 minutes, the absorbance at 550 nm was measured.
Cell viability (%) was then measured using the following equation (1).
&Quot; (1) "
Cell survival rate (%) =
S: △ O.D. optical density of sample
C: OD of control
The cell survival rate was found to be 90% or more at 100, 250, 500 and 1000 μg / mL of the extracts. In other words, it was confirmed that the extracts of the fungus did not show cytotoxicity and thus were safe (Fig. 1).
(2) Measurement of nitric oxide (NO) formation inhibitory effect
Nitric oxide (NO) production inhibitory effect of the extract was determined. At this time, the content of nitrogen monoxide (NO) was measured by the Griess method.
BV-2 cells were seeded in 96-well plates at a concentration of 1 × 10 5 cells / mL using RPMI-1640 medium, and then the test samples (100, 250, 500 or 1000 μg / mL, respectively) and Lipopolysaccharide (LPS) (100 ng / mL) were cultured for 24 hours. 100 μL of cell culture supernatant and 100 μL of Griess reagent (1% sulfanilamide, 0.1% naphthylethylendiamine in 2.5% phosphoric acid) were mixed and reacted for 10 minutes on a 96-well plate. Absorbance was measured at 540 nm using an ELISA reader.
Then, a standard curve was created with sodium nitrate to calculate the content of nitrogen monoxide (NO).
As a result, in the samples treated with LPS alone, nitrogen monoxide (NO) was found to be about 20.06 μM, which produced about 9 times more nitrogen monoxide than the group not treated with LPS. In the case of the sample treated with the extract of the fungus extract at a concentration of 100 to 1000 μg / mL, it was confirmed that the production of nitrogen monoxide (NO) was inhibited in a concentration-dependent manner, and the results are shown in FIG.
As described above, it was confirmed that the fragrant extract of the present invention showed antioxidant or anti-inflammatory effects, and that the fragrant extract contained 12 to 14 mg / g of polyphenol and 3 to 6 mg / g of flavonoid .
The radical scavenging activity of the extracts was 3.16, 20.53 and 63.16% at 10, 50 and 100 μg / mL, respectively. The RC 50 value was 83.96 μg / mL, indicating excellent DPPH radical scavenging activity .
As can be seen from the measurement results of the NO scavenging activity for measuring the anti-inflammatory activity of the fragrant extract of the present invention, it can be confirmed that the fragrant extract inhibits the production of nitrogen monoxide (NO).
That is, it can be confirmed that the composition comprising the extract of the present invention can perform an antioxidant or anti-inflammatory function.
Claims (11)
Wherein the simulated extract comprises polyphenol containing flavonoids. ≪ RTI ID = 0.0 > 11. < / RTI >
Wherein said extract is an ethanol extract.
Wherein said extract is extracted at 20 to 100 DEG C for 10 to 100 hours.
Wherein said composition activates radical scavenging.
Lt; RTI ID = 0.0 > (NO). ≪ / RTI >
Wherein said similitude extract weakens the production of nitrogen monoxide (NO) at a concentration of 100 to 1000 μg / mL.
For 1 mg of the crude extract,
12 to 14 [mu] g of said polyphenols, and 3 to 6 [mu] g of said flavonoids.
Wherein the food is a beverage, a candy, or a task stream.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150077153A KR20160141463A (en) | 2015-06-01 | 2015-06-01 | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150077153A KR20160141463A (en) | 2015-06-01 | 2015-06-01 | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160141463A true KR20160141463A (en) | 2016-12-09 |
Family
ID=57574646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150077153A KR20160141463A (en) | 2015-06-01 | 2015-06-01 | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160141463A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101867492B1 (en) * | 2016-12-28 | 2018-06-14 | 대구대학교 산학협력단 | Composition for Radical Scavenging and α-Glucosidase Inhibitory comprising Gallic Acid Reactants Using Polyphenol Oxidase |
| KR20210066746A (en) * | 2019-11-28 | 2021-06-07 | 대한민국(산림청 국립산림과학원장) | A novel constituent derived from Aralia cordata and uses thereof |
| KR20210066192A (en) * | 2019-11-28 | 2021-06-07 | 대한민국(산림청 국립산림과학원장) | A novel constituent derived from Aralia cordata and an anti-inflammatory composition comprising thereof |
-
2015
- 2015-06-01 KR KR1020150077153A patent/KR20160141463A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101867492B1 (en) * | 2016-12-28 | 2018-06-14 | 대구대학교 산학협력단 | Composition for Radical Scavenging and α-Glucosidase Inhibitory comprising Gallic Acid Reactants Using Polyphenol Oxidase |
| KR20210066746A (en) * | 2019-11-28 | 2021-06-07 | 대한민국(산림청 국립산림과학원장) | A novel constituent derived from Aralia cordata and uses thereof |
| KR20210066192A (en) * | 2019-11-28 | 2021-06-07 | 대한민국(산림청 국립산림과학원장) | A novel constituent derived from Aralia cordata and an anti-inflammatory composition comprising thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tadić et al. | Anti-inflammatory, gastroprotective, free-radical-scavenging, and antimicrobial activities of hawthorn berries ethanol extract | |
| Al-Snafi | A review on Fagopyrum esculentum: A potential medicinal plant | |
| EP2391374B1 (en) | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome | |
| KR100486763B1 (en) | Extracts of Phyllostachys edulis leaf having antioxidant activity and the process for preparation thereof | |
| KR102710828B1 (en) | Composition for preventing and improving viral infectious diseases | |
| KR20160141463A (en) | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis | |
| KR101751590B1 (en) | An anti-inflammatory Cosmetic Composition comprising the extracts of Allium sativum L. stems | |
| KR20200000272A (en) | Composition for anti-oxidant and anti-inflammatory comprising extracts of Lonicera japonica, Glycyrrhiza uralensis, Mentha piperascens, Artemisia princeps and Nelumbo nucifera and manufacturing method thereof | |
| KR101831981B1 (en) | Composition for preventing, improving or treating cancer comprising Sageretia thea extract or its fraction as effective component | |
| Maroof et al. | Medicinal benefits of propolis | |
| KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| KR20160098571A (en) | COMPOSITION COMPRISING EXTRACT OF Carex scabrifolia Steud HAVING ANTI-INFLAMMATORY AND ANTI-OXIDANT ACTIVITY | |
| KR101193558B1 (en) | An anti-inflammatory pharmaceutical composition comprising of extracts as an effective component from Laminaria japonica | |
| KR20180065419A (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
| KR101529279B1 (en) | Liver cytoprotective composition comprising an extract of brassica juncea coss. and compounds isolated therefrom | |
| KR20160042349A (en) | Antioxidant or immunostimulating composition comprising artemisia annua l. baby leaf extract | |
| KR101786180B1 (en) | Composition comprising Spirodela polyrhiza extracts for preventing or treating nonalcoholic fatty liver disease | |
| KR102621205B1 (en) | An anti-oxidant and anti-inflammatory composition comprising extracts of lacquer tree, fluafomitella fraxinea and kudingcha | |
| KR102214014B1 (en) | Antioxidant or anticancer composition comprising extract of Osmanthus heterophylla leaf | |
| KR101890345B1 (en) | Composition for preventing or treating metabolic disease comprising extracts of red pepper seed and pine bark | |
| US20230134529A1 (en) | Labisia pumila extract composition and its pharmaceutical formulation | |
| KR20120037145A (en) | Composition for preventing or treating obesity or hyperlipidemia containing piper longum extract, isoflavon and l-carnitin | |
| KR100857691B1 (en) | Composition for inhibiting development diabetes induced complication containing elsholtzia ciliata extract | |
| Kamran | Olive (Olea europaea L.) leaf biophenols as nutraceuticals | |
| KR20160098567A (en) | Composition comprising extract of rhododendron micranthum having anti-oxidant and anti-inflammatory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |